Montalvo-Ortiz, Janitza L. http://orcid.org/0000-0002-7657-8365
Cheng, Zhongshan
Kranzler, Henry R. http://orcid.org/0000-0002-1018-0450
Zhang, Huiping
Gelernter, Joel http://orcid.org/0000-0002-4067-1859
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (5T32 MH14276)
National Alliance for Research on Schizophrenia and Depression (25191)
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (R01 DA12690)
U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism (R01 AA11330, P50 AA12870)
Article History
Received: 15 October 2018
Accepted: 4 March 2019
First Online: 15 March 2019
Change Date: 5 December 2019
Change Type: Correction
Change Details: An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Competing Interests
: Dr. Kranzler has been an advisory board member, consultant, or CME speaker for Alkermes, Indivior and Lundbeck. He is also a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which was supported in the last three years by AbbVie, Alkermes, Ethypharm, Indivior, Lilly, Lundbeck, Otsuka, Pfizer, Arbor, and Amygdala Neurosciences. Drs Kranzler and Gelernter are named as inventors on PCT patent application #15/878,640 entitled: “Genotype-guided dosing of opioid agonists,” filed January 24, 2018. Drs Montalvo-Ortiz, Cheng and Zhang reported no biomedical financial interests or potential conflicts of interest.